首页> 外文OA文献 >Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery
【2h】

Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery

机译:评估白内障手术中标准化的前房内注射用散瞳药和麻醉药的疗效和安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND/AIMS:To compare the efficacy and safety of intracameral (IC) administration at the beginning of cataract surgery, of Mydrane, a standardised ophthalmic combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1%, to a standard topical regimen.METHODS:In this international phase III, prospective, randomised study, the selected eye of 555 patients undergoing phacoemulsification with intraocular lens (IOL) implantation received 200 μL of Mydrane (Mydrane group) just after the first incision or a topical regimen of one drop each of tropicamide 0.5% and phenylephrine 10% repeated three times (reference group). The primary efficacy variable was achievement of capsulorhexis without additional mydriatics. The non-inferiority of Mydrane to the topical regimen was tested. The main outcome measures were pupil size, patient perception of ocular discomfort and safety.RESULTS:Capsulorhexis without additional mydriatics was performed in 98.9% of patients and 94.7% in the Mydrane and reference groups, respectively. Both groups achieved adequate mydriasis (>7 mm) during capsulorhexis, phacoemulsification and IOL insertion. IOL insertion was classified as 'routine' in a statistically greater number of eyes in the Mydrane group compared with the reference group (p=0.047). Patients in the Mydrane group reported statistically greater comfort than the reference group before IOL insertion (p=0.034). Safety data were similar between groups.CONCLUSIONS:Mydrane is an effective and safe alternative to standard eye drops for initiating and maintaining intraoperative mydriasis and analgesia. Patients who received IC Mydrane were significantly more comfortable before IOL insertion than the reference group. Surgeons found IOL insertion less technically challenging with IC Mydrane.TRIAL REGISTRATION NUMBER:NCT02101359; Results.
机译:背景/目的:为了比较白内障手术开始时进行的前房内(IC)给药的有效性和安全性,Mydrane是一种标准的局部用药方案,该药是0.02%tropicamide,0.31%去氧肾上腺素和1%利多卡因的标准化眼科组合。 :在这项国际性的III期前瞻性随机研究中,刚开始切口或局部用药时,在第一次切口后或每只一滴的局部治疗方案中,对555例接受人工晶状体(IOL)超声乳化白内障超声乳化术的患者的选定眼睛进行了200μLMydrane(Mydrane组)治疗重复进行3次托卡特胺0.5%和去氧肾上腺素10%(参考组)。主要功效变量是没有其他散瞳症的撕囊病。测试了Mydrane对局部用药方案的非劣效性。结果:主要结果指标是瞳孔大小,患者对眼部不适的感觉和安全性。结果:Mydrane组和参考组分别进行98.9%的患者和94.7%的患者进行无附加散瞳的撕囊术。两组在撕囊,超声乳化和人工晶状体植入期间均达到了适当的散瞳(> 7mm)。与参考组相比,在Mydrane组中,在统计学上更多的眼睛中,IOL插入被分类为“常规”(p = 0.047)。 Mydrane组的患者报告说在插入IOL之前,舒适度高于参考组(p = 0.034)。组之间的安全性数据相似。结论:Mydrane是标准滴眼液的有效和安全替代方案,可用于启动和维持术中瞳孔散大和镇痛。接受IC Mydrane的患者在插入IOL之前比参考组更舒适。外科医生发现,使用Mydrane IC进行IOL插入在技术上不那么困难。试验注册号:NCT02101359;结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号